Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells.
AMP-Activated Protein Kinase Kinases
Adenocarcinoma, Scirrhous
/ genetics
Aged
Apoptosis
Biomarkers, Tumor
/ genetics
Cell Proliferation
Female
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Mutation
Prognosis
Protein Serine-Threonine Kinases
/ genetics
Stomach Neoplasms
/ genetics
Survival Rate
Tumor Cells, Cultured
Journal
Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055
Informations de publication
Date de publication:
13 11 2020
13 11 2020
Historique:
received:
22
11
2019
revised:
20
03
2020
accepted:
30
03
2020
pubmed:
3
4
2020
medline:
27
5
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
Scirrhous-type gastric carcinoma (SGC), which is characterized by the rapid proliferation of cancer cells accompanied by extensive fibrosis, shows extremely poor survival. A reason for the poor prognosis of SGC is that the driver gene responsible for SGC has not been identified. To identify the characteristic driver gene of SGC, we examined the genomic landscape of six human SGC cell lines of OCUM-1, OCUM-2M, OCUM-8, OCUM-9, OCUM-12 and OCUM-14, using multiplex gene panel testing by next-generation sequencing. In this study, the non-synonymous mutations of serine threonine kinase 11/liver kinase B1 (STK11/LKB1) gene were detected in OCUM-12, OCUM-2M and OCUM-14 among the six SGC cell lines. Capillary sequencing analysis confirmed the non-sense or missense mutation of STK11/LKB1 in the three cell lines. Western blot analysis showed that LKB1 expression was decreased in OCUM-12 cells and OCUM-14 cells harboring STK11/LKB1 mutation. The mammalian target of rapamycin (mTOR) inhibitor significantly inhibited the proliferation of OCUM-12 and OCUM-14 cells. The correlations between STK11/LKB1 expression and clinicopathologic features of gastric cancer were examined using 708 primary gastric carcinomas by immunochemical study. The low STK11/LKB1 expression group was significantly associated with SGC, high invasion depth and frequent nodal involvement, in compared with the high STK11/LKB1 expression group. Collectively, our study demonstrated that STK11/LKB1 mutation might be responsible for the progression of SGC, and suggested that mTOR signaling by STK11/LKB1 mutation might be one of therapeutic targets for patients with SGC.
Identifiants
pubmed: 32236518
pii: 5814657
doi: 10.1093/carcin/bgaa031
doi:
Substances chimiques
Biomarkers, Tumor
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
STK11 protein, human
EC 2.7.11.1
AMP-Activated Protein Kinase Kinases
EC 2.7.11.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1616-1623Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.